Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kaiping Luo

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Biomedicines|October 29, 2025
Programmed-Cell-Death-Related Signature Reveals Immune Microenvironment Characteristics and Predicts Therapeutic Response in Diffuse Large B Cell LymphomaDonghui Xing, Kaiping Luo, Xiang He, et al.
Frontiers in Pharmacology|February 3, 2022
Efficacy and Safety of Different Immunosuppressive Therapies in Patients With Membranous Nephropathy and High PLA2R Antibody TiterLe Deng, Qipeng Huang, Jiang Wang, et al.
BMC Nephrology|October 15, 2025
Efficacy and safety of hydroxychloroquine in IgA nephropathy with nasopharyngeal or intestinal mucosal and non-mucosal infectionsRan Zhang, Yang Yang, Yan Yan, et al.
EMBO Molecular Medicine|October 14, 2025
Glycine decarboxylase advances IgA nephropathy by boosting mesangial cell proliferation through the pyrimidine pathwayYi Xiong, Fang Zeng, Kaiping Luo, et al.
Current Molecular Medicine|January 16, 2026
A Cuproptosis-related lncRNA Signature for Prognostic Stratification and Immunotherapeutic Implications in Lung AdenocarcinomaYanan Jiang, Donghui Xing, Kaiping Luo, et al.
European Journal of Pharmacology|May 19, 2025
Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stageYang Yang, Yuxin Zhang, Ran Zhang, et al.
Drug Design, Development and Therapy|May 19, 2026
Is Rituximab Suitable for Patients with Idiopathic Membranous Nephropathy Who are Seronegative for Anti-PLA2R Antibody?Yang Yang, Xiaojie Xie, Fan Yuan, et al.
Frontiers in Immunology|April 3, 2026
A multicenter retrospective cohort study on the efficacy and safety of mycophenolate mofetil plus hydroxychloroquine therapy in IgA nephropathyYang Yang, Jing Ning, Fang Zeng, et al.
Cell Death Discovery|May 1, 2024
The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemiaWenqi Wu, Yanan Jiang, Donghui Xing, et al.
Frontiers in Pharmacology|March 19, 2025
Efficacy and safety of Kunxian in IgA nephropathyYang Yang, Xiang Li, Honghong Zou, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Biomedicines|October 29, 2025
Programmed-Cell-Death-Related Signature Reveals Immune Microenvironment Characteristics and Predicts Therapeutic Response in Diffuse Large B Cell LymphomaDonghui Xing, Kaiping Luo, Xiang He, et al.
Frontiers in Pharmacology|February 3, 2022
Efficacy and Safety of Different Immunosuppressive Therapies in Patients With Membranous Nephropathy and High PLA2R Antibody TiterLe Deng, Qipeng Huang, Jiang Wang, et al.
BMC Nephrology|October 15, 2025
Efficacy and safety of hydroxychloroquine in IgA nephropathy with nasopharyngeal or intestinal mucosal and non-mucosal infectionsRan Zhang, Yang Yang, Yan Yan, et al.
EMBO Molecular Medicine|October 14, 2025
Glycine decarboxylase advances IgA nephropathy by boosting mesangial cell proliferation through the pyrimidine pathwayYi Xiong, Fang Zeng, Kaiping Luo, et al.
Current Molecular Medicine|January 16, 2026
A Cuproptosis-related lncRNA Signature for Prognostic Stratification and Immunotherapeutic Implications in Lung AdenocarcinomaYanan Jiang, Donghui Xing, Kaiping Luo, et al.
European Journal of Pharmacology|May 19, 2025
Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stageYang Yang, Yuxin Zhang, Ran Zhang, et al.
Drug Design, Development and Therapy|May 19, 2026
Is Rituximab Suitable for Patients with Idiopathic Membranous Nephropathy Who are Seronegative for Anti-PLA2R Antibody?Yang Yang, Xiaojie Xie, Fan Yuan, et al.
Frontiers in Immunology|April 3, 2026
A multicenter retrospective cohort study on the efficacy and safety of mycophenolate mofetil plus hydroxychloroquine therapy in IgA nephropathyYang Yang, Jing Ning, Fang Zeng, et al.
Cell Death Discovery|May 1, 2024
The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemiaWenqi Wu, Yanan Jiang, Donghui Xing, et al.
Frontiers in Pharmacology|March 19, 2025
Efficacy and safety of Kunxian in IgA nephropathyYang Yang, Xiang Li, Honghong Zou, et al.
Pageof 3